VJHemOnc is committed to improving our service to you

SOHO 2020 | Duvelisib for COVID-19

VJHemOnc is committed to improving our service to you

John DiPersio

John DiPersio, MD, PhD, Washington University, St. Louis, MO, outlines a study evaluating the use of duvelisib, a PI3K inhibitor, for COVID-19, an agent initially investigated due to its identification as a mediator of immune response in models for cytokine release syndrome (NCT04372602). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter